Victory Capital Management Inc. Reduces Stock Holdings in United Therapeutics Corporation $UTHR

Victory Capital Management Inc. lowered its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 72.3% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 109,755 shares of the biotechnology company’s stock after selling 286,900 shares during the quarter. Victory Capital Management Inc.’s holdings in United Therapeutics were worth $46,010,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. AXQ Capital LP raised its stake in shares of United Therapeutics by 495.4% in the second quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company’s stock valued at $1,117,000 after acquiring an additional 3,235 shares during the period. AE Wealth Management LLC lifted its holdings in shares of United Therapeutics by 396.3% in the 3rd quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock worth $1,798,000 after acquiring an additional 3,424 shares during the last quarter. Great Lakes Advisors LLC boosted its stake in shares of United Therapeutics by 194.7% during the 3rd quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock worth $1,888,000 after purchasing an additional 2,975 shares during the period. Optimize Financial Inc purchased a new position in shares of United Therapeutics during the 3rd quarter worth about $444,000. Finally, Simplify Asset Management Inc. bought a new position in United Therapeutics during the 3rd quarter valued at about $8,351,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Down 1.4%

Shares of UTHR stock opened at $478.16 on Friday. The firm has a market cap of $20.96 billion, a price-to-earnings ratio of 17.14, a PEG ratio of 1.72 and a beta of 0.84. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $537.19. The company’s 50 day moving average is $482.51 and its 200 day moving average is $453.25.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. The company had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.United Therapeutics’s revenue was up 7.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $6.19 earnings per share. Analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on UTHR. Wells Fargo & Company increased their price objective on shares of United Therapeutics from $423.00 to $466.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 26th. TD Cowen upped their target price on United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Oppenheimer increased their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Bank of America reissued a “neutral” rating on shares of United Therapeutics in a research note on Wednesday, February 25th. Finally, UBS Group boosted their price target on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a report on Thursday. Nine equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $539.00.

United Therapeutics News Summary

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: UBS raised its price target on UTHR from $655 to $705 and kept a Buy rating — a notable analyst endorsement implying material upside that could attract buyers. Read More.
• Neutral Sentiment: Multiple sell‑side firms have recently increased targets and reiterated Buy/outperform views (Oppenheimer, HC Wainwright, TD Cowen); consensus remains a “Moderate Buy” with a mid‑range price target, supporting a constructive medium‑term thesis. Read More.
• Negative Sentiment: A wave of insider selling this week is pressuring sentiment: CEO Martine Rothblatt sold 9,500 shares (~$4.65M), and several directors/executives (Ray Kurzweil, Paul Mahon, Tommy G. Thompson and others) also sold blocks at roughly $483–$490 per share. These large, concentrated disposals can prompt near‑term weakness even if insiders retain stakes. Read More. Read More.

Insider Buying and Selling at United Therapeutics

In related news, CFO James Edgemond sold 21,000 shares of the company’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $478.60, for a total transaction of $10,050,600.00. Following the completion of the sale, the chief financial officer directly owned 8,142 shares in the company, valued at $3,896,761.20. This represents a 72.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $496.30, for a total value of $11,166,750.00. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 377,184 shares of company stock valued at $183,015,947. Corporate insiders own 10.30% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.